En español
NIDA

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1) PAR-16-357

Revised June 2017

Frequently Asked Questions

Does the concept or the application of technology proposed have to be completely novel or just new to the field of substance abuse research? 
While applicants are encouraged to propose completely novel approaches, existing approaches novel to the field of substance abuse research are also encouraged. Emphasis is placed on 1) the importance of the scientific problem and the potential impact of the research on the genetics and epigenetics of substance abuse, 2) the novelty and innovativeness of the approach, and 3) evidence of the applicant's potential for creative and innovative research as an early stage investigator.

Do applicants need to be trained in the field of substance abuse? 
No.  However it would be prudent for applicants without such training to enlist the support of substance use disorder experts as collaborators.  It would likely be beneficial for any substance abuse collaborator to review the Avenir proposal prior to submission.  Applicants invited for the interview phase of the review should again enlist the support of substance abuse disorder collaborators to better prepare for the interview and possible subsequent steps.

Why was the Avenir Award for Genetics or Epigenetics of Substance Use FOA changed from an RFA to a PAR? 
It was changed to give NIDA greater budgetary flexibility.  An RFA (Request for Applications) requires that funds be set aside to pay meritorious applications.  In contrast, a PAR does not require that funds be set aside; in the absence of a set-aside, meritorious applications compete for the larger RPG pool of funds.  

What is the DP1 mechanism?
This award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction.  These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of substance use disorders.  The program may also support investigators outside the field of addiction who are interested in applying their novel approaches to the genetics or epigenetics of addiction.  The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.

What are the next application due dates? 
October 19, 2017; October 19, 2018, by 5:00 PM local time of applicant organization.  Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Who is eligible to apply? 
Applicants must meet the definition of an Early Stage Investigator (ESI). An ESI is a new investigator (defined as a PD/PI who has not competed successfully for a significant NIH independent research award) who is within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent). A complete list of NIH grants that do not disqualify a PD/PI as a new investigator can be found at: https://grants.nih.gov/grants/new_investigators/. Frequently Asked Questions about the NIH Early Stage Investigator (ESI) Policy can be found at https://grants.nih.gov/grants/new_investigators/.

An extension to the 10-year period may be granted under special circumstances (e.g., family care responsibilities, extended periods of clinical training, disability or illness, etc.). To request an extension, an applicant MUST complete the “Form for Requesting an Extension in the Early Stage Investigator (ESI) Period” (https://grants.nih.gov/grants/new_investigators/esi_extension_add.htm). A request for extension must be approved at the time the Avenir Award application is submitted. It may take up to several weeks for the approval process, so applicants should plan accordingly.

By what date must an investigator hold an independent position to be eligible to apply for the Avenir Award in Genetics and Epigenetics? 
Applicants must hold an independent research position at a domestic (U.S.) institution as of September 1 of the fiscal year of the competition. Investigators still in training or mentored status (postdoctoral fellows) are not eligible to apply unless they have a written commitment of an independent faculty position as of September 1 of the fiscal year of the competition that is certified by submission of the application from that institution.

What is meant by “independent research position?
For the purpose of this award, “independent research position” means a position that automatically confers eligibility, according to the applicant’s institutional policy, for an investigator to apply for R01 grants with an appropriate commitment of facilities to be used for the conduct of the proposed research. Investigators still in training or mentored status (postdoctoral fellows) are not eligible to apply unless they have a written commitment of an independent faculty position as of September 1 of the fiscal year in which they are applying for the Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP1), which is certified by submission of the application from that institution.

What percent effort is expected for the Avenir Award. 
At least 25% effort is expected.

Can an applicant submit an R01 at the same time? 
Yes.  Applicants may submit or have an R01 (or other equivalent) grant application pending concurrently with their Avenir Award application. If the applicant receives an R01 before the Avenir can be awarded, then the investigator is no longer eligible for an Avenir award.  

What is the page limit for the Research Plan? 
5 pages

What should be included in the Research Plan? 
Specific Aims must not be included.  The research strategy should include 1) An Essay; 2) Statement of research effort commitment of at least 25%; 3) Project Description; 4) Investigator Qualifications.  Please see announcement for complete details.

What letters are needed? 
Letters of support from significant collaborators should be included in the application.  In addition, three letters of reference are needed.  The three confidential letters of reference are to be submitted separately from the application through the ERA Commons.

What Information does the applicant need to provide to referees for them to properly submit a letter of reference?

The referee will need the following information:

  • Funding Opportunity Number (FOA) for this announcement: PAR-16-357
  • The applicant’s eRA Commons User Name (Note: Referees do not need to be registered in the Commons and do not need their own Commons User Name – only the Commons User Name of the applicant is required);
  • The applicant’s first and last name (note – the name must match exactly the applicant’s name in the Commons);
  • The URL to the letter submission page (https://public.era.nih.gov/commons/public/reference/submitReferenceLetter.do?mode=new)
  • Confirmation Number (Required only when resubmitting a letter, that is, when submitting a revised or changed/corrected letter for the current FOA)
  • Letters of reference are confidential. Applicants will not have access to the letters. Email confirmations will be sent to both the applicant and the referee. The confirmation sent to the applicant will include the referee’s name and the date and time the letter was submitted.  The confirmation sent to the referee will include the referee and applicant’s names, a confirmation number, and the date and time the letter was submitted.

What are the instructions to the referees?

Letters are to be submitted to the Commons at (https://public.era.nih.gov/commons/public/reference/submitReferenceLetter.do?mode=new) by September 20, 2017 no later than 5PM local time for an application deadline of October 19, 2017 or September 20, 2018 not later than 5PM local time when the applicant is submitting for the October 19, 2018 deadline. 

The applicant’s name should be placed at the top of the letter. Although signatures are not required, the letter must include a signature block with the referee’s full name, title, institution, and contact information.

In two pages or less, describe the applicant’s qualities that support the applicant’s claim to scientific innovativeness and creativity. When possible, give specific examples that illustrate these qualities. Address the likelihood that the applicant will conduct groundbreaking research in the proposed research area.

Note: The letter submission page can be accessed without signing into the Commons, and referees do not need to be registered in the Commons. Referees must provide the applicant’s Commons User Name (User ID) and the other information below:

REFEREE INFORMATION (the individual providing the letter of reference):

Referee’s First and Last Name (Required)

Referee’s Middle Initial (MI) (Not Required)

Referee’s Email Address (Required)

Referee’s Institution/Affiliation (Required)

Referee’s Department (Required)

Can you tell me about the review process? 
Applications that are complete are reviewed in two phases by a multidisciplinary scientific review group of outside experts convened by The National Institute on Drug Abuse in accordance with NIH peer review procedures (http://grants1.nih.gov/grants/peer/).   Applications will initially be evaluated for scientific and technical merit by outside reviewers. Subsequently, an editorial-style panel will consider the applications and the comments of the initial reviewers to select the most meritorious applications. Less meritorious applications will not be discussed.  Candidates with more meritorious applications selected by the panel will be invited to the Washington, D.C. area in February of March for interviews. 

If I am not interviewed, will I receive a score? 
For those who are not interviewed, their summary statements will indicate that their application was “Not Discussed”.  Nonetheless, the summary statements will contain the criterion scores and evaluative comments of individual reviewers.

When will the awards be announced?
No later than September of that Fiscal Year if a meritorious award is identified and selected.  The U.S. Government Fiscal Year ends September 30.

How will final selection be made?
Final selection of awardees will be made by the Director, National Institute on Drug Abuse, NIH, based on the outcome of the initial peer review, concurrence of National Advisory Council on Drug Abuse, and programmatic considerations. Final selections will be announced publicly.

 

This page was last updated June 2017